Katrina Carli, MD
Nephrology · Everett, WANPI 1407112337
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.3% of the total across 21 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 13 manufacturers, the largest accounting for just 23.2% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $284, 6.7 times the $42 reported in 2019.
Across 21 payments — averaging $21.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$107
- AstraZeneca$68
- Scpharmaceuticals Inc.$48
- Lilly USA, LLC$34
- Merck$31
- Otsuka America Pharmaceutical, Inc.$30
- plus $144 from 7 others
What the payments were for
- Food & beverage$45799%
- Education$31%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 4 | $107 |
| AstraZeneca | 3 | $68 |
| Scpharmaceuticals Inc. | 2 | $48 |
| Lilly USA, LLC | 1 | $34 |
| Merck | 1 | $31 |
| Otsuka America Pharmaceutical, Inc. | 2 | $30 |
| Boston Scientific | 1 | $28 |
| Travere Therapeutics, Inc. | 2 | $25 |
| Bayer | 1 | $24 |
| Calliditas Therapeutics US Inc. | 1 | $18 |
| GSK | 1 | $18 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $16 |
| Vifor Pharma, Inc. | 1 | $14 |
How this compares
$460 in reported general payments places this provider in the 65th percentile of 237 nephrology providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 32 | $39,480 |
| ClinolipidFat Emulsion/Olive/Soy/Phospho | 20 | $7,452 |
| Sevelamer Carbonate | 20 | $3,884 |
| Calcium Acetate | 16 | $2,946 |
| Torsemide | 51 | $1,922 |
| Amlodipine Besylate | 128 | $1,202 |
| Losartan Potassium | 86 | $981 |
| Gentamicin Sulfate | 19 | $931 |
| Carvedilol | 84 | $928 |
| Bumetanide | 15 | $693 |
| Potassium Chloride | 20 | $466 |
| Hydralazine Hcl | 43 | $448 |
| Furosemide | 68 | $444 |
| Metoprolol Succinate | 33 | $423 |
| Nifedipine ErNifedipine | 12 | $332 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Everett
- Thao PascualEverett$5K
- Josef Edrik Keith BautistaEverett$3K
- Kathrine TuttleSpokane$421K
- Osama AmroSeattle$395K
- Dmitri VasinBremerton$215K
- Ian de BoerSeattle$117K
- Nicolae LecaSeattle$101K
- Syeda AhmadSeattle$68K
- Charles MinnTacoma$67K
- Saw Hnin MuShoreline$25K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.